| Year |
Title |
Altmetric |
| 2021
|
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis.
Journal of Internal Medicine.
290:310-334.
2021
|
|
| 2020
|
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
JAMA Neurology.
77:215-224.
2020
|
|
| 2019
|
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Lancet Neurology.
18:549-558.
2019
|
|
| 2019
|
Description of process and content of online dementia coaching for family caregivers of persons with dementia.
Healthcare.
7.
2019
|
|
| 2019
|
Alabama brief cognitive screener: Utility of a new cognitive screening instrument in a memory disorders clinic
2019
|
|
| 2017
|
Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease.
Neurobiology of Aging.
49:216.e7.
2017
|
|
| 2016
|
Glucocerebrosidase, Parkinson disease, and the “senses and intellect”.
Annals of Neurology.
80:660-661.
2016
|
|
| 2016
|
Qualitative assessment of self-identity in people with advanced dementia
2016
|
|
| 2014
|
Can a Memory Club Help Maintain Cognitive Function? A Pilot Investigation
2014
|
|
| 2014
|
Implications of early treatment among Medicaid patients with Alzheimer's disease.
Alzheimer's and Dementia.
10:214-224.
2014
|
|
| 2013
|
Family composition and expressions of family-focused care needs at an academic memory disorders clinic.
International Journal of Alzheimer's Disease.
2013.
2013
|
|
| 2013
|
Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: An evidence-based approach
2013
|
|
| 2013
|
Pre-diagnosis excess acute care costs in alzheimer's patients among a US medicaid population.
Applied Health Economics and Health Policy.
11:407-413.
2013
|
|
| 2013
|
High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines
2013
|
|
| 2012
|
Challenges and opportunities for characterizing cognitive aging across species.
Frontiers in Aging Neuroscience.
4.
2012
|
|
| 2012
|
Characterizing cognitive aging in humans with links to animal models.
Frontiers in Aging Neuroscience.
4.
2012
|
|
| 2012
|
Characterizing healthy samples for studies of human cognitive aging.
Frontiers in Aging Neuroscience.
4.
2012
|
|
| 2012
|
Parkinson disease: Research update and clinical management.
Southern Medical Journal.
105:650-656.
2012
|
|
| 2012
|
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: A subgroup analysis in patients already taking or not taking concomitant memantine.
Dementia and Geriatric Cognitive Disorders.
33:164-173.
2012
|
|
| 2012
|
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
American Journal of Alzheimer's Disease and Other Dementias.
27:421-432.
2012
|
|
| 2011
|
Family quality of life in dementia: A qualitative approach to family-identified care priorities.
Quality of Life Research.
20:1331-1335.
2011
|
|
| 2011
|
Targets of the peroxisome proliferator - activated receptor γ agonist trials for the prevention of Alzheimer disease: Reply.
Archives of Neurology.
68:542-543.
2011
|
|
| 2011
|
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with alzheimer disease.
Archives of Neurology.
68:45-50.
2011
|
|
| 2010
|
Alzheimer disease prevention: Focus on cardiovascular risk, not amyloid?.
Cleveland Clinic Journal of Medicine.
77:689-704.
2010
|
|
| 2008
|
Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.
Neuropsychiatric Disease and Treatment.
4:549-555.
2008
|
|
| 2008
|
Vascular myelopathies.
CONTINUUM: Lifelong Learning in Neurology.
14:71-90.
2008
|
|
| 2007
|
Acetylcholinesterase inhibitors for Alzheimer's disease.
Aging Health.
3:483-494.
2007
|
|
| 2007
|
MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia [6].
Neurology.
69:321.
2007
|
|
| 2007
|
Treatment guidelines for Alzheimer's disease: Redefining perceptions in primary care
2007
|
|
| 2006
|
Conduction aphasia as a function of the dominant posterior perisylvian cortex: Report of two cases.
Journal of Neurosurgery.
104:845-848.
2006
|
|
| 2006
|
Realistic expectations for treatment success in Alzheimer's disease.
Journal of Nutrition, Health and Aging.
10:417-429.
2006
|
|
| 2005
|
Erratum: Donepezil (Aricept®) for the treatment of Alzheimer's disease and other dementing conditions (Expert Review of Neurotherapeutic (January 2004) 4, 1 (5-16))
2005
|
|
| 2005
|
The cost benefit to health plans of pharmacotherapy for Alzheimer's disease.
2005
|
|
| 2004
|
Fulfilling expectations.
Annals of Long-Term Care.
12:46-48.
2004
|
|
| 2004
|
Maintaining patients with Alzheimer's disease in the home environment.
Advanced Studies in Medicine.
4:308-313.
2004
|
|
| 2004
|
Differential diagnosis of dementia syndromes..
Clinics in Geriatric Medicine.
20:27-43.
2004
|
|
| 2004
|
Dementia with Lewy bodies: Diagnosis and clinical approach.
Cleveland Clinic Journal of Medicine.
71:789-800.
2004
|
|
| 2004
|
Differential diagnosis of dementia syndromes.
Clinics in Geriatric Medicine.
20:27-43.
2004
|
|
| 2004
|
Donepezil (Aricept®) for treatment of Alzheimer's disease and other dementing conditions
2004
|
|
| 2004
|
Interdisciplinary approaches to Alzheimer's disease management.
Clinics in Geriatric Medicine.
20:121-139.
2004
|
|
| 2003
|
Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician.
2003
|
|
| 2003
|
Visuospatial dysfunction in the neurodegenerative diseases.
Frontiers in Bioscience.
8.
2003
|
|
| 2003
|
Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Stroke.
34:2323-2330.
2003
|
|
| 2003
|
Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.
Journal of the American Geriatrics Society.
51:937-944.
2003
|
|
| 2003
|
Alzheimer's disease: Current pharmacotherapy in the context of patient and family needs.
Journal of the American Geriatrics Society.
51.
2003
|
|
| 2003
|
Development of a scale to predict decline in patients with mild Alzheimer's disease.
Journal of the American Geriatrics Society.
51:91-95.
2003
|
|
| 2003
|
Donepezil in Vascular Dementia: A Viewpoint.
Drugs and Aging.
20:1137.
2003
|
|
| 2003
|
Visuospatial dysfunction in the neurodegenerative diseases..
Frontiers in Bioscience.
8.
2003
|
|
| 2002
|
Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias.
Journal of the American Geriatrics Society.
50:1871-1878.
2002
|
|
| 2002
|
Medication use in Alzheimer's disease and healthy aging: Results from a research registry
2002
|
|
| 2002
|
Cost-effective recognition and diagnosis of dementia.
Seminars in Neurology.
22:63-70.
2002
|
|
| 2002
|
Quality of Life and Deficit Identification in Dementia
2002
|
|
| 2001
|
Apathy in Alzheimer's disease.
Journal of the American Geriatrics Society.
49:1700-1707.
2001
|
|
| 2001
|
DNA replication precedes neuronal cell death in Alzheimer's disease
2001
|
|
| 2001
|
Contemporary drug treatment
2001
|
|
| 2001
|
Providing care for the caregiver
2001
|
|
| 2001
|
Open-label, multicenter, phase 3, extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
Archives of Neurology.
58:427-433.
2001
|
|
| 2000
|
Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons.
Neurobiology of Aging.
21:797-806.
2000
|
|
| 2000
|
Conflicting priorities in Alzheimer's care, primary care, and managed care: Who pays the price?.
American Journal of Managed Care.
6.
2000
|
|
| 2000
|
Effects of stimulus properties and age on random-array letter cancellation tasks
2000
|
|
| 1999
|
Age effects on random-array letter cancellation tests
1999
|
|
| 1999
|
Spatial aspects of letter cancellation performance in arabic readers.
International Journal of Neuroscience.
97:29-39.
1999
|
|
| 1999
|
Three-dimensional neglect phenomena following right anterior choroidal artery infarction.
Journal of the International Neuropsychological Society.
5:567-571.
1999
|
|
| 1998
|
Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain
1998
|
|
| 1998
|
Clock drawing test in very mild Alzheimer's disease.
Journal of the American Geriatrics Society.
46:1266-1269.
1998
|
|
| 1998
|
Stimulus characteristics determine processing approach on random array letter-cancellation tasks.
Brain and Cognition.
36:346-354.
1998
|
|
| 1998
|
The effect of character and array type on visual spatial search quality following traumatic brain injury.
Brain Injury.
12:69-76.
1998
|
|
| 1997
|
Activities of daily living as an outcome measure in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Alzheimer Disease and Associated Disorders.
11:6-7.
1997
|
|
| 1997
|
Clinical experience with donepezil hydrochloride: A case study perspective.
Advances in Therapy.
14:305-311.
1997
|
|
| 1997
|
Objective psychometric tests in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Alzheimer Disease and Associated Disorders.
11:34-38.
1997
|
|
| 1997
|
Donepezil (aricept) therapy for alzheimer's disease.
Comprehensive Therapy.
23:492-493.
1997
|
|
| 1997
|
Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope.
Alzheimer Disease and Associated Disorders.
11.
1997
|
|
| 1997
|
Differential diagnosis of Alzheimer's disease.
Neurology.
48.
1997
|
|
| 1997
|
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study..
Alzheimer Disease and Associated Disorders.
11 Suppl 2:S13-S21.
1997
|
|
| 1997
|
Effect of stimulus number, target-to-distractor ratio, and motor speed on visual spatial search quality following traumatic brain injury.
Brain Injury.
11:59-66.
1997
|
|
| 1997
|
Enhancing recovery from ischemic stroke.
Neurosurgery Clinics of North America.
8:245-251.
1997
|
|
| 1997
|
Ethical issues in dementia drug development: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Alzheimer Disease and Associated Disorders.
11:26-28.
1997
|
|
| 1997
|
Treatment of functional decline in adults with down syndrome using selective serotonin-reuptake inhibitor drugs.
Journal of Geriatric Psychiatry and Neurology.
10:99-104.
1997
|
|
| 1996
|
Current concepts: Evaluation of dementia.
New England Journal of Medicine.
335:330-336.
1996
|
|
| 1996
|
Effects of stimulus number and target-to-distractor ratio on the performance of random array letter cancellation tasks.
Brain and Cognition.
32:405-415.
1996
|
|
| 1996
|
Executive functions and Alzheimer's disease: Problems and prospects.
European Journal of Neurology.
3:5-15.
1996
|
|
| 1995
|
Letter cancellation performance in alzheimer’s disease
1995
|
|
| 1994
|
Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition [1].
Journal of Clinical Psychiatry.
55:161.
1994
|
|
| 1994
|
Pharmacotherapy for Alzheimer's disease.
Clinics in Geriatric Medicine.
10:339-350.
1994
|
|
| 1994
|
Spatial performance bias in normal elderly subjects on aletter cancellation task
1994
|
|
| 1994
|
Visual field influence on radial line bisection.
Brain and Cognition.
26:65-72.
1994
|
|
| 1993
|
Nonoptic aphasia: Aphasia with preserved confrontation naming in alzheimer's disease.
Neurology.
43:1900-1907.
1993
|
|
